BCL2 and ovarian carcinoma: Similarly, another BCL‐2 inhibitor, ABT‐263 (Navitoclax), was reported to eliminate senescent cells and enhance the efficacy of olaparib, a poly(ADP‐ribose) polymerase (PARP) inhibitor, in both breast and ovarian cancer cell lines [85].